GSK, Theravance report completion of Relovair studies in COPD and asthma – Pharmaceutical Business Review


Visit Bulgaria

GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review
GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma.
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)
Theravance Falls Most in 3 Years After Glaxo Drug FailsBusinessWeek
Glaxo on the slide after trials setback for asthma drugEvening Standard
Visit Bulgaria –TheStreet.com –Wall Street Journal (India)
all 64 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.